This ground-breaking collaboration will enhance accuracy and efficiency of immunotherapy response for improved patient outcomes LOS ANGELES and VALENCIA, Spain, May 2, 2023 /PRNewswire/ — ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™)…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.